Healthcare / Diagnostics & ResearchASX
$2.12
-0.06 (-2.75%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $27.4M · quality 59.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$791M
P/E
53.0x
↑EV/EBITDA
13.5x
↑ROE
0.7%
↑Gross Margin
95.5%
↑Debt/Equity
0.84
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+20.5%
FCF CAGR
+14.5%
FCF margin
2.2%
FCF / Net income
3.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $627.2M · net income $4.7M · FCF $14.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $627.2M | $627.2M | $469.7M | $440.1M | $358.7M |
| Net Income | $4.7M | $4.7M | $-60.7M | $25.0M | $14.6M |
| EBITDA | $87.7M | $87.7M | $6.7M | $92.5M | $69.7M |
| EPS | 0.02 | 0.02 | -0.26 | 0.11 | 0.07 |
| Gross Margin | 95.5% | 95.5% | 95.1% | 95.2% | 94.6% |
| Operating Margin | 9.2% | 9.2% | 9.0% | 8.9% | 10.2% |
| Net Margin | 0.7% | 0.7% | -12.9% | 5.7% | 4.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.84 | 0.84 | 1.19 | 0.98 | 0.98 |
| Current Ratio | 0.63 | 0.63 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $14.0M | $14.0M | $42.3M | $27.4M | $9.3M |
| Returns | |||||
| ROE | 0.7% | 0.7% | -20.1% | 6.7% | 4.2% |
| Valuation | |||||
| P/E | 53.00 | 53.00 | — | 29.72 | 42.61 |
| EV/EBITDA | 13.49 | 13.49 | 137.35 | 11.63 | 12.04 |
| P/B | 0.94 | 0.94 | 2.02 | 1.99 | 1.79 |
| Growth & Yield | |||||
| Revenue Growth | 33.5% | 33.5% | 6.7% | 22.7% | — |
| EPS Growth | 106.2% | 106.2% | -345.3% | 53.6% | — |
| Dividend Yield | 3.1% | 3.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
127.4%
EPS terminal req.
$0.19
Spread vs growth
-21.2%
5Y implied EPS CAGR
70.1%
EPS terminal req.
$0.23
Spread vs growth
36.1%
10Y implied EPS CAGR
36.8%
EPS terminal req.
$0.37
Spread vs growth
69.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-6.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.26 → 0.02
Residual
-9.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.